Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial.
Matas J., Orrego M., Amenabar D., Infante C., Tapia-Limonchi R., Cadiz MI.
Randomized Controlled Trial with a reported sample of 8 on Knee Osteoarthritis, Osteoarthritis, published in Stem Cells Transl Med (2018) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- Stem Cells Transl Med (2018)
- Country
- England
- Reported sample size
- 8
- Source database
- PubMed
- PMID
- 30592390
- DOI
- 10.1002/sctm.18-0053
- NCT
- NCT02580695
Abstract (original English)
Knee osteoarthritis (OA) is a leading cause of pain and disability. Although conventional treatments show modest benefits, pilot and phase I/II trials with bone marrow (BM) and adipose-derived (AD) mesenchymal stromal cells (MSCs) point to the feasibility, safety, and occurrence of clinical and structural improvement in focal or diffuse disease. This study aimed to assess the safety and efficacy of the intra-articular injection of single or repeated umbilical cord-derived (UC) MSCs in knee OA. UC-MSCs were cultured in an International Organization for Standardization 9001:2015 certified Good Manufacturing Practice-type Laboratory. Patients with symptomatic knee OA were randomized to receive hyaluronic acid at baseline and 6 months (HA, n = 8), single-dose (20 × 10 6 ) UC-MSC at baseline (MSC-1, n = 9), or repeated UC-MSC doses at baseline and 6 months (20 × 10 6 × 2; MSC-2, n = 9). Clinical scores and magnetic resonance images (MRIs) were assessed throughout the 12 months follow-up. No severe adverse events were reported. Only MSC-treated patients experienced significant pain and function improvements from baseline (p = .001). At 12 months, Western Ontario and Mc Master Universities Arthritis Index (WOMAC-A; pain subscale) reached significantly lower levels of pain in the MSC-2-treated group (1.1 ± 1.3) as compared with the HA group (4.3 ± 3.5; p = .04). Pain Visual Analog scal
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Clinical Outcomes of Biologic Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Studies With ≥12-Month Follow-up.
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Mod Rheumatol (2026) — summary generated from the PubMed abstract.
- 2026
Mod Rheumatol - Level AMeta-analysisEurope PMC
Towards optimized rehabilitation with regenerative therapy: A systematic review and meta-analysis on the effects of cell-based injections for knee osteoarthritis
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Sports Traumatol Arthrosc (2026) — summary generated from the PubMed abstract.
- 2026
Knee Surg Sports Traumatol Arthrosc - Level ASystematic ReviewPubMed
Intra-articular fat grafting for pain relief and functioning improvement in patients with knee osteoarthritis: systematic review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Disabil Rehabil (2026) — summary generated from the PubMed abstract.
- 2026
Disabil Rehabil - Level ASystematic ReviewPubMed
Research Landscape of Stem Cell Applications in Musculoskeletal Tissue: A Scoping Review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level AMeta-analysisEurope PMC
Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis
Meta-analysis with a reported sample of 5251 on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Relat Res (2026) — summary generated from the PubMed abstract.
- 2026
- n = 5251
Knee Surg Relat Res